Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,609 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (799)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07566585 | Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation | withdrawn | Phase 1 | 0 | BlueSphere Bio, IncINDUSTRY | 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT07338357 | Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML | withdrawn | Early Phase 1 | 0 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07387354 | Pacritinib With Aza for Upfront Myelodysplastic Syndrome(MDS) | withdrawn | Phase 1 / Phase 2 | 0 | Thomas Jefferson UniversityOTHER | 0 | Aug 17, 2026 | clinicaltrials |
| NCT05115344 | Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors | withdrawn | Phase 1 | 0 | Guizhou Bailing Group Pharmaceutical Co LtdINDUSTRY | 0 | Aug 13, 2026 | clinicaltrials |
| NCT06903702 | A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT06290765 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera(PV) | withdrawn | Phase 4 | 0 | PharmaEssentiaINDUSTRY | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07084584 | ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Galecto Biotech ABINDUSTRY | 0 | Jul 6, 2026 | clinicaltrials |
| NCT04953312 | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)(CALPRO) | withdrawn | N/A | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | withdrawn | Phase 1 | 0 | Ossium Health, Inc.INDUSTRY | 0 | Feb 24, 2026 | clinicaltrials |
| NCT06284460 | Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | withdrawn | N/A | 0 | Neena Kapoor, M.D.OTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | withdrawn | Phase 1 | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 22, 2025 | clinicaltrials |
| NCT05248685 | Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Beijing Boren HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03560908 | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | withdrawn | Phase 1 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05595135 | Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study | withdrawn | N/A | 0 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06351306 | DEC-C and Thioguanine for R/R AML | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Mar 24, 2025 | clinicaltrials |
| NCT06113289 | A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06200441 | Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease | withdrawn | — | 0 | Ugur Arzu KuluOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03939585 | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT | withdrawn | Phase 1 | 0 | Leland MethenyOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05266950 | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Guenther KoehneOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05823480 | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05854966 | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML(Pediatric AML) | withdrawn | Phase 1 | 0 | Elucida OncologyINDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT04955938 | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | withdrawn | Phase 2 | 0 | Northside Hospital, Inc.OTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05309018 | Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML(LAMIPA) | withdrawn | — | 0 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | withdrawn | Phase 1 / Phase 2 | 0 | Indiana UniversityOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 11, 2024 | clinicaltrials |
| NCT02734823 | Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05720988 | Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06085638 | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS(MAGROLIC) | withdrawn | Phase 2 | 0 | Uwe PlatzbeckerOTHER | 0 | Feb 12, 2024 | clinicaltrials |
| NCT06180863 | Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04361058 | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias | withdrawn | Phase 1 | 0 | Juan C. Ramos, MDOTHER | 0 | Dec 4, 2023 | clinicaltrials |
| NCT05943314 | Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia | withdrawn | N/A | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT04629651 | Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT05456269 | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS(BISECT) | withdrawn | Phase 1 | 0 | Racura Oncology LtdINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
Data updated 18 days agoSource updated Sep 11, 2026source: clinicaltrials